2020: Our Extraordinary Year in DiDi Numbers
29.1.2021 04:00:00 EET | Business Wire | Press release
2020 was a year like no other for the world, for DiDi’s nearly 600 million users and driver partners, as well as its 13,000 corporate employees. At the dawn of a new year of hope, we would like to take some time to look back at some of the highlights in 2020 to celebrate the resilience of our people and cities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128006172/en/
DiDi 2020 in Numbers (Graphic: Didi Chuxing)
- Protecting local communities is our utmost priority.
Offline, more than 11 million sets of free masks and sanitizers were distributed to millions of drivers and couriers worldwide throughout 2020. DiDi driver-managers helped install 1 million protective dividers in DiDi cars to prevent droplet infection. Hi-tech or low-tech, we went the full distance for tech that works.
Online, all of DiDi’s 30 million+ driver partners went through a Health Guard routine that includes mask, temperature and disinfection checks to log onto daily service.
We stand ready to help our cities. Globally, hundreds of thousands of DiDi drivers and couriers provided more than 6 million free or discounted rides and meals to frontline health care workers and those in need. From mask verification to contact tracing, our engineers open-sourced various technological tools for cities around the world.
- Our safety standards are higher and stronger.
Internationally, major safety incidents on DiDi dropped by 50.8% year-on-year. In-trip disputes and conflicts were down by 42.3%. Sexual-related complaints dropped by 71.4%.
This was made possible by continued safety investments. Across our international markets, DiDi’s risk analysis and management algorithms activated over 361 million control acts ranging from safety reminders, extra verifications, warnings and all the way to geo-fencing and active individual interventions.
But we couldn’t have done it without you and your safety awareness. Drivers and riders outside China chose to activate advanced safety options over 25 million times. In-trip audio recording was used over 1.3 million times. Over 23 million trips were shared with trusted ones.
- With these solid health and safety bottom lines, we helped build stronger and more inclusive communities.
Globally, over 4 million drivers and couriers registered to use DiDi’s platform in 2020, many of whom were looking for extra income opportunities to tackle the challenges arising from the pandemic. Of the newly registered driver partners in international markets in 2020, 13.6% are women. Together with our female employees that account for 40% of DiDi’s workforce, women drivers helped us build higher platform standards of diversity and inclusion.
- Together with these partners, we were able to stay resilient and achieve new growth.
Global daily trips hit a new record high of 60 million in October 2020. We also launched multiple new services including group-buying, courier, and freight businesses to capture demands arising from new consumer dynamics. As businesses focus more on efficiency, DiDi Enterprise Solutions, which helps cut employee and business transportation costs, also saw a 12% year-on-year growth in its client base.
In 2020, six new markets were opened – Russia, Peru, Panama, Argentina, the Dominican Republic and New Zealand. Trips completed outside China reached 1 billion.
-
Finally, our numbers also reflected special moments of life in every city we operate:
- Small businesses are true warriors: A food shop-owner in Brazil, our star user globally, completed 2,017 trips in 2020 for in-person delivery.
- There is always one long ride we have to take in life: A Brazilian user took a trip of 999.7 kilometers in 2020.
- Good food comforts us and makes things right: The most frequent DiDi Food user, a Mexican gourmet, completed 749 orders from 216 restaurants in 2020.
- The most popular time of the day to place a food delivery order was 3pm in Mexico, 7pm in Japan and 8pm in Brazil.
- In 2020, the most ordered items in Japan, Mexico and Brazil was large-size beef noodles, traditional pepperoni pizza, beef and chicken burger, respectively.
In times of uncertainty, we heard more stories of love, perseverance and our shared fighting spirit. Kudos to all! We will be back together, back stronger as 2021 brings renewed hopes and commitments.
About Didi Chuxing
Didi Chuxing (“DiDi”) is the world’s leading mobile transportation and local services platform. The company offers a full range of app-based services for over 550 million users across Asia Pacific, Latin America and Russia, including taxi-hailing, private car-hailing, P2P rideshare, bus, bikes & e-bikes, designated driving, automobile solutions, delivery and logistics, and financial services. Tens of millions of car owners, drivers and delivery partners who find flexible work and income opportunities on DiDi platform provide over 10 billion passenger trips a year. Daily trip volume for DiDi’s core mobility services exceeds 60 million during the first week of October 2020.
DiDi is committed to collaborating with policymakers, the taxi industry, the automobile industry and our communities to solve the world’s transportation, environmental and employment challenges with localized smart transportation innovations by leveraging its AI capabilities. We will strive non-stop to create better life experience and greater social value, through building a safe, inclusive and sustainable transportation and local services ecosystem for cities of the future.
For more information, please visit: www.didiglobal.com/news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128006172/en/
Contact information
Media Enquiry:
Didi Chuxing
globalpr@didiglobal.com
Sard Verbinnen & Co
DidiChuxing@sardverb.com
US +1 415 618 8750
HK +852 3842 2200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
